Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing
Source: SeekingAlpha
2026-05-02 03:20:18 ET
If you vaguely follow big pharma, then you have probably heard of something called a patent cliff, which is when a company has multiple patents expiring within a short timeframe. Though patent expiration may be better for the consumer, it essentially means that any company can now manufacture and sell patented drugs that were once exclusive to one company. This undercuts the pricing power of the company that had the initial patent, destroying profit margins for that product....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing
Gilead Sciences Inc.
NASDAQ: GILD
GILD Trading
1.87% G/L:
$131.47 Last:
3,249,390 Volume:
$130.09 Open:
GILD Latest News
June 05, 2026 03:00:00 am
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
GILD Stock Data
$185,419,569,657
1,228,272,827
0.07%
1237
N/A
Pharmaceuticals
Healthcare
US
Foster City
